BioCentury | Aug 4, 2016
Translation in Brief

CAR checkpoints

...& Centers for Cell Engineering & Cellular Therapeutics at MSKCC and an associate professor of cardiothoracic...
BioCentury | Apr 21, 2014
Company News

Harvard Apparatus Regenerative management update

...Apparatus Regenerative Technology Inc. (NASDAQ:HART), Holliston, Mass. Business: Gene/Cell therapy Hired: Saverio La Francesca, a cardiothoracic...
BioCentury | Apr 25, 2013
Tools & Techniques

Regenerating the kidney

...platform technology and not just applicable to a single organ," said Ott, a fellow in cardiothoracic...
BioCentury | Mar 14, 2013
Tools & Techniques

VentriGel goes into pigs

...in patients already undergoing surgery to restore cardiac function, said Harald Ott, a fellow in cardiothoracic...
BioCentury | Jun 13, 2011
Clinical News

S: Phase II/III discontinued

...futility criteria" (see BioCentury, April 18). The trial had planned to enroll 8,044 patients undergoing cardiothoracic...
...following elective cardiothoracic surgery Endpoint: Incidence of serious S. aureus infections for 90 days following cardiothoracic...
BioCentury | Apr 18, 2011
Clinical News

S: Phase II/III suspended enrollment

...the additional analyses have been completed. The trial had planned to enroll 8,044 patients undergoing cardiothoracic...
...following elective cardiothoracic surgery Endpoint: Incidence of serious S. aureus infections for 90 days following cardiothoracic...
BioCentury | Apr 18, 2011
Finance

Risk/benefit uncertainty

...immunogenic surface-expressed hemoglobin receptor. The Phase II/III trial is in patients who have undergone elective cardiothoracic...
BioCentury | Apr 12, 2011
Clinical News

Intercell falls on Staph vaccine setback

...enrollment in a Phase II/III trial of V710 to prevent Staphylococcus aureus infections following elective cardiothoracic...
...the additional analyses have been completed. The trial had planned to enroll 8,044 patients planning cardiothoracic...
BioCentury | Nov 22, 2010
Clinical News

S: Phase II data

...Phase II/III trial of the vaccine to prevent S. aureus infections in patients undergoing elective cardiothoracic...
BioCentury | Oct 7, 2010
Targets & Mechanisms

Getting to the essence of Staph

...Phase II portion of a Phase II/III study that is immunizing about 8,000 patients undergoing cardiothoracic...
Items per page:
1 - 10 of 37
BioCentury | Aug 4, 2016
Translation in Brief

CAR checkpoints

...& Centers for Cell Engineering & Cellular Therapeutics at MSKCC and an associate professor of cardiothoracic...
BioCentury | Apr 21, 2014
Company News

Harvard Apparatus Regenerative management update

...Apparatus Regenerative Technology Inc. (NASDAQ:HART), Holliston, Mass. Business: Gene/Cell therapy Hired: Saverio La Francesca, a cardiothoracic...
BioCentury | Apr 25, 2013
Tools & Techniques

Regenerating the kidney

...platform technology and not just applicable to a single organ," said Ott, a fellow in cardiothoracic...
BioCentury | Mar 14, 2013
Tools & Techniques

VentriGel goes into pigs

...in patients already undergoing surgery to restore cardiac function, said Harald Ott, a fellow in cardiothoracic...
BioCentury | Jun 13, 2011
Clinical News

S: Phase II/III discontinued

...futility criteria" (see BioCentury, April 18). The trial had planned to enroll 8,044 patients undergoing cardiothoracic...
...following elective cardiothoracic surgery Endpoint: Incidence of serious S. aureus infections for 90 days following cardiothoracic...
BioCentury | Apr 18, 2011
Clinical News

S: Phase II/III suspended enrollment

...the additional analyses have been completed. The trial had planned to enroll 8,044 patients undergoing cardiothoracic...
...following elective cardiothoracic surgery Endpoint: Incidence of serious S. aureus infections for 90 days following cardiothoracic...
BioCentury | Apr 18, 2011
Finance

Risk/benefit uncertainty

...immunogenic surface-expressed hemoglobin receptor. The Phase II/III trial is in patients who have undergone elective cardiothoracic...
BioCentury | Apr 12, 2011
Clinical News

Intercell falls on Staph vaccine setback

...enrollment in a Phase II/III trial of V710 to prevent Staphylococcus aureus infections following elective cardiothoracic...
...the additional analyses have been completed. The trial had planned to enroll 8,044 patients planning cardiothoracic...
BioCentury | Nov 22, 2010
Clinical News

S: Phase II data

...Phase II/III trial of the vaccine to prevent S. aureus infections in patients undergoing elective cardiothoracic...
BioCentury | Oct 7, 2010
Targets & Mechanisms

Getting to the essence of Staph

...Phase II portion of a Phase II/III study that is immunizing about 8,000 patients undergoing cardiothoracic...
Items per page:
1 - 10 of 37